$16.27
5.35% today
Nasdaq, Sep 04, 04:47 pm CET
ISIN
IL0011280240
Symbol
ARCT

Arcturus Therapeutics Ltd Stock price

$17.19
+4.99 40.90% 1M
+1.51 9.63% 6M
+0.22 1.30% YTD
-2.20 11.35% 1Y
+2.87 20.04% 3Y
-21.78 55.89% 5Y
-37.27 68.44% 10Y
-35.66 67.47% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.49 2.93%
ISIN
IL0011280240
Symbol
ARCT
Industry

Key metrics

Basic
Market capitalization
$466.8m
Enterprise Value
$270.3m
Net debt
positive
Cash
$196.5m
Shares outstanding
27.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.8 | 4.7
EV/Sales
2.2 | 2.7
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
70.0%
Return on Equity
-33.6%
ROCE
-27.6%
ROIC
-79.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$122.1m | $100.3m
EBITDA
$-69.3m | $-98.6m
EBIT
$-72.6m | $-81.7m
Net Income
$-60.2m | $-70.3m
Free Cash Flow
$-65.2m
Growth (TTM | estimate)
Revenue
-25.5% | -34.1%
EBITDA
19.1% | -7.1%
EBIT
18.6% | 14.6%
Net Income
16.4% | 13.1%
Free Cash Flow
8.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-56.7% | -98.3%
EBIT
-59.4%
Net
-49.3% | -70.1%
Free Cash Flow
-53.4%
More
EPS
$-2.2
FCF per Share
$-2.4
Short interest
29.3%
Employees
175
Rev per Employee
$870.0k
Show more

Is Arcturus Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Arcturus Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Arcturus Therapeutics Ltd forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Arcturus Therapeutics Ltd forecast:

Buy
94%
Hold
6%

Financial data from Arcturus Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
122 122
25% 25%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 47 47
11% 11%
39%
- Research and Development Expense 147 147
26% 26%
121%
-69 -69
19% 19%
-57%
- Depreciation and Amortization 3.31 3.31
4% 4%
3%
EBIT (Operating Income) EBIT -73 -73
19% 19%
-59%
Net Profit -60 -60
16% 16%
-49%

In millions USD.

Don't miss a Thing! We will send you all news about Arcturus Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcturus Therapeutics Ltd Stock News

Neutral
Business Wire
9 days ago
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conferences: Citi's 2025 Biopharm...
Neutral
Seeking Alpha
24 days ago
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q2 2025 Earnings Conference August 11, 2025 4:30 PM ET Company Participants Andrew H. Sassine - CFO & Director Joseph E.
Neutral
Business Wire
24 days ago
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the second quarter ended June 30, 2025, and provided corporate upda...
More Arcturus Therapeutics Ltd News

Company Profile

Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Head office Israel
CEO Joseph Payne
Employees 175
Founded 2013
Website arcturusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today